Glivec decision raises more questions about the Indian IP Office
The Indian IP Appeal Board's decision to reject a Novartis patent application relating to the Glivec anti-cancer treatment gets an extensive review on the Spicy IP blog. The board gives a number of reasons for the rejection, but one rings very…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.